The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome

Annales d'Endocrinologie

Volumn 76, Issue 5, 2015, Pages 620-627

  Yang, Hai Yan ^a   Ma, Yan ^a   Lu, Xin Hong ^a   Liang, Xing Huan ^a   Suo, Ying Jun ^a   Huang, Zhen Xing ^a   Lu, De Cheng ^a   Qin, Ying Fen ^a   Luo, Zuo Jie ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

BMI; Omentin 1; PCOS

Indexed keywords

FOLLITROPIN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; MEMBRANE PROTEIN; OMENTIN 1; SEX HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG; CYTOKINE; GLUCOSE BLOOD LEVEL; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CHINESE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; HOMEOSTASIS; HORMONE DETERMINATION; HUMAN; INSULIN RESISTANCE; LUTEINIZING HORMONE FOLLICLE STIMULATING HORMONE RATIO; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; ORGAN SIZE; OVARY POLYCYSTIC DISEASE; OVARY VOLUME; PHYSICAL PARAMETERS; PROTEIN DETERMINATION; PROTEIN FUNCTION; ADOLESCENT; ANALYSIS; BLOOD; BODY WEIGHT; CASE CONTROL STUDY; CHINA; CROSS-SECTIONAL STUDY; GLUCOSE BLOOD LEVEL; OBESITY; OVARY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; CHINA; CROSS-SECTIONAL STUDIES; CYTOKINES; FASTING; FEMALE; FOLLICLE STIMULATING HORMONE; GPI-LINKED PROTEINS; HUMANS; INSULIN; INSULIN RESISTANCE; LECTINS; LUTEINIZING HORMONE; OBESITY; OVARY; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; YOUNG ADULT;

EID: 84946722419     PISSN: 00034266     EISSN: 22133941     Source Type: Journal    
DOI: 10.1016/j.ando.2015.08.002     Document Type: Article

References (41)

1. Broekmans F.J., Knauff E.A., Valkenburg O., Laven J.S., Eijkemans M.J., Fauser B.C. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 2006, 113:1210-1217.
2. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89:2745-2749.
3. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 2005, 352:1223-1236.
4. Rotterdam EA-SPCWG Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25.
5. Goodarzi M.O., Korenman S.G. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 2003, 80:255-258.
6. Fauser B.C., Tarlatzis B.C., Rebar R.W., Legro R.S., Balen A.H., Lobo R., et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012, 97. 28-38 e25.
7. Wild R.A., Carmina E., Diamanti-Kandarakis E., Dokras A., Escobar-Morreale H.F., Futterweit W., et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010, 95:2038-2049.
8. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
9. Deepa S.S., Dong L.Q. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 2009, 296:E22-E36.
10. Pittas A.G., Joseph N.A., Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004, 89:447-452.
11. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261.
12. Xiang K., Wang Y., Zheng T., Jia W., Li J., Chen L., et al. Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes 2004, 53:228-234.
13. de Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.M., Yu D.Z., Pray J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
14. Pan H.Y., Guo L., Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010, 88:29-33.
15. Kuperman D.A., Lewis C.C., Woodruff P.G., Rodriguez M.W., Yang Y.H., Dolganov G.M., et al. Dissecting asthma using focused transgenic modeling and functional genomics. J Allergy Clin Immunol 2005, 116:305-311.
16. Xue Y., Jiang L., Cheng Q., Chen H., Yu Y., Lin Y., et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One 2012, 7:e46740.
17. Zhang Y.Y., Zhou L.M. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. Eur J Pharmacol 2013, 698:137-144.
18. Maruyama S., Shibata R., Kikuchi R., Izumiya Y., Rokutanda T., Araki S., et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012, 287:408-417.
19. Galluzzo A., Amato M.C., Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 2008, 18:511-518.
20. Carmina E., Bucchieri S., Esposito A., Del Puente A., Mansueto P., Orio F., et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 2007, 92:2500-2505.
21. Tan B.K., Adya R., Farhatullah S., Lewandowski K.C., O'Hare P., Lehnert H., et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
22. Chen X., Yang D., Mo Y., Li L., Chen Y., Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol 2008, 139:59-64.
23. Li R., Zhang Q., Yang D., Li S., Lu S., Wu X., et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod 2013, 28:2562-2569.
24. Li J., Fan S., Li Y., Chen J., Cao J., Huang J., et al. [Incidence of obesity and its modifiable risk factors in Chinese adults aged 35-74 years: a prospective cohort study]. Zhonghua Liu Xing Bing Xue Za Zhi 2014, 35:349-353.
25. Rotterdam EA-SPcwg Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19:41-47.
26. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
27. Sample W.F., Lippe B.M., Gyepes M.T. Gray-scale ultrasonography of the normal female pelvis. Radiology 1977, 125:477-483.
28. Organization WH The Asia-Pacific perspective: redefining obesity and its treatment 2000, [Retrieved October 09, 2012].
29. Xing X., Yang W., Yang Z. The diagnostic significance of homeostasis model assessment of insulin resistance in metabolic syndrome among subjects with different glucose tolerance. Chin J Diabetes 2004, 12:182-186.
30. Despres J.P., Lemieux I., Bergeron J., Pibarot P., Mathieu P., Larose E., et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28:1039-1049.
31. Guzel E.C., Celik C., Abali R., Kucukyalcin V., Celik E., Guzel M., et al. Omentin and chemerin and their association with obesity in women with polycystic ovary syndrome. Gynecol Endocrinol 2014, 30:419-422.
32. Zhang Q., Zhu L., Zheng M., Fan C., Li Y., Zhang D., et al. Changes of serum omentin-1 levels in normal subjects, type 2 diabetes and type 2 diabetes with overweight and obesity in Chinese adults. Ann Endocrinol (Paris) 2014, 75:171-175.
33. Campos D.B., Palin M.F., Bordignon V., Murphy B.D. The 'beneficial' adipokines in reproduction and fertility. Int J Obes (Lond) 2008, 32:223-231.
34. Choi J.H., Rhee E.J., Kim K.H., Woo H.Y., Lee W.Y., Sung K.C. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol 2011, 165:789-796.
35. Orlik B., Madej P., Owczarek A., Skalba P., Chudek J., Olszanecka-Glinianowicz M. Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2013, 81:529-535.
36. Ouwens D.M., Bekaert M., Lapauw B., Van Nieuwenhove Y., Lehr S., Hartwig S., et al. Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome. Arch Physiol Biochem 2012, 118:135-138.
37. Tan B.K., Pua S., Syed F., Lewandowski K.C., O'Hare J.P., Randeva H.S. Decreased plasma omentin-1 levels in type 1 diabetes mellitus. Diabet Med 2008, 25:1254-1255.
38. Adams-Huet B., Devaraj S., Siegel D., Jialal I. Increased adipose tissue insulin resistance in metabolic syndrome: relationship to circulating adipokines. Metab Syndr Relat Disord 2014, 12:503-507.
39. Chang R.J., Nakamura R.M., Judd H.L., Kaplan S.A. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983, 57:356-359.
40. Pache T.D., Chadha S., Gooren L.J., Hop W.C., Jaarsma K.W., Dommerholt H.B., et al. Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome?. Histopathology 1991, 19:445-452.
41. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991, 12:3-13.